Literature DB >> 25598492

Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients.

Jessica Frau1, Davide Cossu2, Giancarlo Coghe3, Lorena Lorefice3, Giuseppe Fenu3, Gianluca Porcu3, Claudia Sardu4, Maria Rita Murru3, Stefania Tranquilli3, Maria Giovanna Marrosu3, Leonardo Antonio Sechi2, Eleonora Cocco3.   

Abstract

BACKGROUND: Mycobacterium avium subspecies paratuberculosis (MAP) is associated with MS in Sardinia. Because anti-MAP antibodies (Abs) were more frequent in interferon-beta treated patients, we hypothesize that interferon-beta could interact with the immune system.
METHODS: Anti-MAP Abs were searched in the blood of 89 patients before commencing interferon-beta and after at least six months.
RESULTS: Anti-MAP Abs were detected before and during treatment in 18.7% and 34.7% of patients, respectively. Twenty-three (20.5%) patients became positive during therapy, and 5 (4.4%) patients became negative (p=0.001).
CONCLUSIONS: The study supports the hypothesis that interferon-beta could interact with the immune system, enhancing the immunological response against MAP.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endocellular pathogen; Immunomodulation; Interferon-beta; Molecular mimicry; Multiple sclerosis; Mycobacterium avium subspecies paratuberculosis

Mesh:

Substances:

Year:  2015        PMID: 25598492     DOI: 10.1016/j.jns.2015.01.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  cGAS-STING-TBK1-IRF3/7 induced interferon-β contributes to the clearing of non tuberculous mycobacterial infection in mice.

Authors:  Nanthapon Ruangkiattikul; Andreas Nerlich; Ketema Abdissa; Stefan Lienenklaus; Abdulhadi Suwandi; Nina Janze; Kristin Laarmann; Julia Spanier; Ulrich Kalinke; Siegfried Weiss; Ralph Goethe
Journal:  Virulence       Date:  2017-04-19       Impact factor: 5.882

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

3.  Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients.

Authors:  Giuseppe Mameli; Davide Cossu; Elisa Caggiu; Giannina Arru; Magdalena Niegowska; Eleonora Cocco; Jessica Frau; Maria Giovanna Marrosu; Leonardo A Sechi
Journal:  J Mol Neurosci       Date:  2016-07-02       Impact factor: 3.444

Review 4.  Mycobacterium avium ss. paratuberculosis Zoonosis - The Hundred Year War - Beyond Crohn's Disease.

Authors:  Leonardo A Sechi; Coad Thomas Dow
Journal:  Front Immunol       Date:  2015-03-04       Impact factor: 7.561

5.  Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system.

Authors:  Davide Cossu; Kazumasa Yokoyama; Yuji Tomizawa; Eiichi Momotani; Nobutaka Hattori
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

Review 6.  Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Eleonora Cocco
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.